gaucher disease - Robuta Search

https://gaucherdiseasenews.com/ Gaucher Disease News Home - Gaucher Disease News gaucher disease news https://pubmed.ncbi.nlm.nih.gov/40083427/ Eliglustat substrate reduction therapy in children with Gaucher disease type 1 Eliglustat demonstrated significant clinical benefits in pediatric GD1 patients, as evidenced by reductions in GlcSph levels and other disease indicators. The... in children gaucher disease eliglustat substrate reduction https://pubmed.ncbi.nlm.nih.gov/33510429/ Predicting the probability of Gaucher disease in subjects with splenomegaly and thrombocytopenia Hematologists are frequently involved in the diagnostic pathway of Gaucher disease type 1 (GD1) patients since they present several hematological signs.... gaucher disease https://pmc.ncbi.nlm.nih.gov/articles/PMC7026612/ Liver involvement in patients with Gaucher disease types I and III - PMC Gaucher disease (GD) is a multisystemic disease. Liver involvement in GD is not well characterised and ranges from hepatomegaly to cirrhosis and hepatocellular... in patients gaucher disease https://my.clevelandclinic.org/health/diseases/16234-gaucher-disease Gaucher Disease: Symptoms, Causes & Treatment Gaucher disease is a lysosomal storage disorder, a type of disease that causes fatty substances to build up in your bone marrow, liver and spleen. gaucher disease symptoms causes treatment https://medicine.yale.edu/internal-medicine/gaucher/event/digestive-diseases-research-semin-14/ Digestive Diseases Week Presentations: Part 2 | National Gaucher Disease Treatment Center 04/21/2026 event at Yale School of Medicine digestive diseases week presentations part https://medicine.yale.edu/internal-medicine/gaucher/event/digestive-diseases-research-semin-23/ Digestive Diseases Research Seminar | National Gaucher Disease Treatment Center 06/23/2026 event at Yale School of Medicine digestive diseases research seminar national gaucher treatment https://medicine.yale.edu/internal-medicine/gaucher/event/liver-center-research-seminar-thomas-f-baumert-md/ Liver Center Research Seminar | National Gaucher Disease Treatment Center 04/07/2026 event at Yale School of Medicine liver center research seminar gaucher disease national treatment https://www.mayoclinic.org/diseases-conditions/gauchers-disease/symptoms-causes/syc-20355546 Gaucher disease - Symptoms and causes - Mayo Clinic The buildup of naturally occurring fatty substances damages the spleen, liver, bones and other tissues. Life-long treatments help manage most cases. gaucher disease symptoms causes mayo clinic https://pubmed.ncbi.nlm.nih.gov/18509745/ Management of non-neuronopathic Gaucher disease with special reference to pregnancy, splenectomy,... Enzyme replacement was introduced as treatment for non-neuronopathic Gaucher disease more than 15 years ago. To ensure the best use of this costly ultra-orphan... gaucher disease https://www.researchandmarkets.com/reports/6082023/substrate-inhibition-therapy-gaucher-disease Substrate Inhibition Therapy of Gaucher Disease Market - Global Forecast 2026-2032 The Substrate Inhibition Therapy of Gaucher Disease Market, valued at USD 2.56B in 2026, is projected to reach USD 3.93B by 2032, growing at a 7.4% CAGR. gaucher disease global forecast substrate inhibition therapy https://www.techtransfer.nih.gov/tech/tab-2252 Glucocerebrosidase Activators as a Treatment for Gaucher Disease | Technology Transfer as a treatment for gaucher disease activators technology https://adisinsight.springer.com/trials/700323948?error=cookies_not_supported&code=887b6735-296c-480b-b86a-8192c094b356 A Pivotal study of Arimoclomol in Gaucher Disease - AdisInsight This study will evaluate Arimoclomol in patients diagnosed with Gaucher Disease. gaucher disease pivotal study arimoclomol adisinsight https://iris.cnr.it/handle/20.500.14243/554413 Identification of Novel Mutations in Patients Affected by Gaucher Disease in patients identification novel mutations affected https://medicine.yale.edu/internal-medicine/gaucher/event/samuel-d-kushlan-md-visiting-professorship-gi-endoscopy-in-patients-on-antithrombotics/ Samuel D. Kushlan, MD, Visiting Professorship Series | National Gaucher Disease Treatment Center 03/18/2026 event at Yale School of Medicine visiting professorship https://www.ebsco.com/research-starters/consumer-health/gauchers-disease Gaucher's disease | Consumer Health | Research Starters | EBSCO Research consumer health gaucher disease research starters https://experts.umn.edu/en/publications/enzyme-replacement-therapy-for-gauchers-disease-in-patient-treate/ Enzyme replacement therapy for Gaucher's disease in patient treated for non-small cell lung cancer... https://www.gaucherschat.com/ Gaucher Exchange - a social network for people with Gaucher's Disease - Gaucher's Chat Gaucher's Chat - A Gaucher's Disease Support Network for people with Gaucher Disease, and their family. a social for people gaucher exchange network https://pmc.ncbi.nlm.nih.gov/articles/PMC3586535/ Safety and efficacy of velaglucerase alfa in Gaucher disease type 1 patients previously treated... Velaglucerase alfa is a glucocerebrosidase produced by gene activation technology in a human fibroblast cell line (HT-1080), and is indicated as an enzyme... safety and efficacy https://experts.umn.edu/en/publications/atypical-presentation-of-primary-stabbing-headache-in-a-patient-w/ Atypical Presentation of Primary Stabbing Headache in a Patient With Type 3 Gaucher Disease -... https://pubmed.ncbi.nlm.nih.gov/40110721/ Never-Treated, Non Splenectomised Patients With Gaucher Disease (The French GANT Study): The... Treatment options for Type 1 Gaucher Disease (GD1) include enzyme replacement therapy and oral substrate reduction therapy. The criteria for treatment... https://medicine.yale.edu/internal-medicine/gaucher/event/digestive-diseases-research-semin-19/ Cumulative Antigen Suppression Reduces Clonal Plasma Cell Evolution in Gaucher Disease 2. Analysis... 05/26/2026 event at Yale School of Medicine